Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Death drive

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    490 result(s) found for: Death drive. Displaying page 1 of 25.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-000671-25 Sponsor Protocol Number: 1242-001 Start Date*: 2016-09-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S...
    Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004565-14 Sponsor Protocol Number: 20170625 Start Date*: 2019-09-13
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardia...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) EE (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002259-39 Sponsor Protocol Number: TL-895-202 Start Date*: 2020-09-23
    Sponsor Name:Telios Pharma, Inc.
    Full Title: A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of COVID-19 in Patients with Cancer
    Medical condition: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in patients with cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002672-40 Sponsor Protocol Number: SGNTUC-029 Start Date*: 2022-09-20
    Sponsor Name:Seagen Inc.
    Full Title: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Su...
    Medical condition: unresectable or metastatic HER2+ colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) SK (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004417-42 Sponsor Protocol Number: MK3475-587 Start Date*: 2018-07-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizuma...
    Medical condition: Advanced Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) LT (Trial now transitioned) GR (Completed) IT (Trial now transitioned) LV (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001398-97 Sponsor Protocol Number: 20110118 Start Date*: 2012-10-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Co...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020604 Hypercholesterolemia LLT
    18.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) PL (Completed) GR (Completed) LT (Completed) BE (Completed) IT (Completed) NL (Completed) DK (Completed) AT (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) EE (Completed) IS (Completed) GB (Completed) DE (Completed) BG (Completed) SE (Completed) LV (Completed) IE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2012-002414-39 Sponsor Protocol Number: MK-3102-018 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002299-28 Sponsor Protocol Number: 20110203 Start Date*: 2017-01-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Redu...
    Medical condition: Chronic Heart Failure With Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) PT (Completed) PL (Completed) AT (Completed) SK (Completed) BG (Completed) LT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003485-11 Sponsor Protocol Number: 1002-043 Start Date*: 2017-02-16
    Sponsor Name:Esperion Therapeutics Inc.,
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardi...
    Medical condition: Patients with, or at high risk for, cardiovascular disease (CVD) who are statin intolerant.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10007541 - Cardiac disorders 10007648 Cardiovascular disease, unspecified LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) LV (Completed) LT (Completed) GB (GB - no longer in EU/EEA) DK (Completed) DE (Completed) HU (Completed) BG (Completed) CZ (Completed) PL (Completed) ES (Completed) HR (Completed) BE (Completed) AT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005278-59 Sponsor Protocol Number: 20050222 Start Date*: 2006-12-22
    Sponsor Name:Amgen Inc.
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symp...
    Medical condition: Heart Failure Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007559 Cardiac failure congestive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) LT (Completed) SK (Completed) BE (Completed) EE (Completed) FI (Completed) HU (Completed) DK (Completed) DE (Completed) CZ (Completed) ES (Completed) SE (Completed) AT (Completed) PT (Completed) NL (Completed) LV (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-005186-20 Sponsor Protocol Number: 7965-012 Start Date*: 2012-07-12
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation.
    Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia (CLL)
    Medical condition: chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) CZ (Completed) SE (Completed) FI (Completed) LT (Prematurely Ended) LV (Completed) ES (Completed) HU (Completed) IT (Completed) PL (Prematurely Ended) BE (Prematurely Ended) GR (Completed) EE (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004359-57 Sponsor Protocol Number: CanStem111P Start Date*: 2017-08-01
    Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc.
    Full Title: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.
    Medical condition: This study will enroll patients with histologically or cytologically confirmed adenocarcinoma of the pancreas that is metastatic (Stage IV).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) BE (Completed) CZ (Completed) AT (Completed) PT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019637-96 Sponsor Protocol Number: YMB1000-018 Start Date*: 2010-12-20
    Sponsor Name:YMBiosciences INC
    Full Title: A Randomized, Phase II, Double-Blind Study of Nimotuzumab Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer
    Medical condition: Brain metastases from Non-Small Cell Lung Cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006719-20 Sponsor Protocol Number: 0431-082 Start Date*: 2009-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
    Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control
    Medical condition: Type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002009-40 Sponsor Protocol Number: MK-3475-045 Start Date*: 2014-09-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
    Medical condition: Metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IE (Completed) IT (Completed) DE (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) SE (Completed) DK (Completed) GB (Completed) PT (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-001814-85 Sponsor Protocol Number: PNT2258-04-Richter's Start Date*: 2016-03-10
    Sponsor Name:ProNAi Therapeutics, Inc.
    Full Title: A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)
    Medical condition: Diffuse large B-cell non-Hodgkin's lymphoma with Richter's Transformation (RT) from chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058728 Richter's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001233-89 Sponsor Protocol Number: SGI-110-04 Start Date*: 2015-05-15
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for I...
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SE (Completed) BE (Completed) HU (Completed) DE (Completed) GB (Completed) NL (Completed) FI (Completed) CZ (Completed) AT (Completed) ES (Completed) PL (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005272-19 Sponsor Protocol Number: 20190184 Start Date*: 2023-01-08
    Sponsor Name:Amgen Inc
    Full Title: EVOLVE-MI: A Pragmatic Randomized Multicenter Trial of EVOLocumab Administered Very Early to Reduce the Risk of Cardiovascular Events in Patients Hospitalized With Acute Myocardial Infarction
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003628-18 Sponsor Protocol Number: 000000 Start Date*: 2020-09-29
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-003698-41 Sponsor Protocol Number: MK-3475-048 Start Date*: 2015-02-19
    Sponsor Name:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc.
    Full Title: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
    Medical condition: Recurrent/metastatic head and neck squamous cell carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) EE (Completed) LV (Completed) DK (Completed) FI (Completed) AT (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) RO (Ongoing) GR (Completed) DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:47:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA